Co-Authors
This is a "connection" page, showing publications co-authored by WILLIAM G WIERDA and BETTY LAMOTHE.
Connection Strength
0.432
-
Carfilzomib Triggers Cell Death in Chronic Lymphocytic Leukemia by Inducing Proapoptotic and Endoplasmic Reticulum Stress Responses. Clin Cancer Res. 2016 Sep 15; 22(18):4712-26.
Score: 0.136
-
Proteasome inhibitor carfilzomib complements ibrutinib's action in chronic lymphocytic leukemia. Blood. 2015 Jan 08; 125(2):407-10.
Score: 0.125
-
Transcriptomic clustering of chronic lymphocytic leukemia: molecular subtypes based on Bruton's tyrosine kinase expression levels. Blood Cancer J. 2024 Dec 18; 14(1):220.
Score: 0.062
-
A Pilot Phase II Study of Erlotinib for the Treatment of Patients with Relapsed/Refractory Acute Myeloid Leukemia. Acta Haematol. 2018; 140(1):30-39.
Score: 0.040
-
Pharmacodynamics and proteomic analysis of acalabrutinib therapy: similarity of on-target effects to ibrutinib and rationale for combination therapy. Leukemia. 2018 04; 32(4):920-930.
Score: 0.038
-
Pharmacological and Protein Profiling Suggests Venetoclax (ABT-199) as Optimal Partner with Ibrutinib in Chronic Lymphocytic Leukemia. Clin Cancer Res. 2015 Aug 15; 21(16):3705-15.
Score: 0.032